

AD _____

GRANT NUMBER DAMD17-94-J-4045

TITLE: Defining the Smallest Common Region of Chromosome 17p
that is Deleted in Sporadic Breast Tumors

PRINCIPAL INVESTIGATOR: Sofia D. Merajver, M.D.

Max S. Wicha, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Michigan
Ann Arbor, Michigan 48109-1274

REPORT DATE: October 1997

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19980408 130

DTIC QUALITY INSPECTED 8

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1997	3. REPORT TYPE AND DATES COVERED Annual (1 Oct 96 - 30 Sep 97)	
4. TITLE AND SUBTITLE Defining the Smallest Common Region of Chromosome 17p that is Deleted in Sporadic Breast Tumors			5. FUNDING NUMBERS DAMD17-94-J-4045	
6. AUTHOR(S) Sofia D. Merajver, M.D. Max S. Wicha, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Michigan Ann Arbor, Michigan 48109-1274			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) Germline mutations in breast cancer susceptibility genes account for 8% of all breast cancer cases. BRCA1 on 17q12 and BRCA2 on 13q12-13 are implicated in 50%-60% of breast cancer families, and they are both likely to also have an impact in sporadic breast cancers and there is evidence for families with linkage to these loci. We propose to ascertain 8 ethnically diverse (non-Caucasian) families linked to putative BRCA3 loci on chromosome 8p, and to investigate whether a recently isolated prostate cancer metastases suppressor gene, KAI1, is involved in the genetic alterations of inflammatory breast cancer, a particularly aggressive form of breast cancer which accounts for 15% of all cases.				
14. SUBJECT TERMS Breast Cancer, Humans, Anatomical Samples, Tumor Suppressor Genes, Allelic Imbalance, Chromosome 17			15. NUMBER OF PAGES 12	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

_____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

_____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

✓ _____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

✓ _____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

✓ _____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

_____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

 12/1/97

PI - Signature Date

Table of Contents

Foreword.....	Page	3
Table of Contents.....	Page	4
Introduction.....	Page	5
Body.....	Page	6
Conclusions.....	Page	10
References.....	Page	10

Introduction

Hereditary breast cancer accounts for 5-8% of breast cancer cases (1). Loci on 8p12-22 are frequently lost in breast tumors and may thus harbor one or more tumor suppressor genes (2). Almost all of breast cancer families studied so far in North America and Western Europe are of Caucasian origin. *We hypothesize that more ethnically diverse families with evidence of autosomal dominant transmission of breast cancer are needed to study loci on 8p12-22.* As current data indicate that *BRCA2* families are rarer than previously predicted, *we hypothesize that a proportion of families found to be unlinked to both BRCA1 and BRCA2 will be linked to recently defined loci on chromosome 8p12-22; as a corollary, the characterization of the 8p-linked familial tumors will help define the limits of the candidate regions on this chromosome.* The specific aims proposed in this application are:

1. To ascertain at least 5 site-specific breast cancer families of diverse ethnic background who are linked to loci on chromosome 8p12-22.
2. To analyze the 8p-linked tumors for LOH at closely spaced markers to help refine the breast cancer candidate region(s).
3. To test families unlinked to *BRCA1*, *BRCA2*, and loci on 8p12-22 for linkage to the *KAI1* gene, a metastases suppressor gene, and to analyze sporadic breast tumors for mutations in *KAI1*.

SIGNIFICANCE AND PRELIMINARY STUDIES

Family collection.

Breast cancer will affect 1,600,000 women world-wide in 1995. In the US alone, 48,000 will die of this disease in 1996 (3). The discovery of breast cancer susceptibility genes has allowed the study of a relatively simple and unique model system for human mammary epithelial carcinogenesis. The tumors suffered by the women belonging to these families are clinically indistinguishable from sporadic tumors. Our laboratory has recently proven that at least 10% of sporadic ovarian cancers undergo inactivation of both *BRCA1* alleles.

The scarcity of African American and other minority families in the study of breast cancer susceptibility genes provides the impetus for this application which combines basic research in molecular genetics of breast cancer with a rational attempt at a minority family collection (5-8). The study of the etiology of the widening gap in survival (3) between Caucasian and African American populations requires that future experiments on cancer susceptibility genes be done on an ethnically balanced population of samples. *The lack of availability of these samples and the long lag-time for their acquisition have invariably been the limiting factors. Our proposal intends to contribute shared resources. The Breast Cancer Tissue Core at the University of Michigan (DOD-funded; S. Ethier, Principal Investigator; S. Merajver, co-investigator) provides an independently funded mechanism to freely share these resources for the next 4 years.*

Epidemiological data on family history and breast cancer incidence on Hispanic, Japanese, and Arab women suggests that familial clustering of breast cancer also appears in these populations (9-11). We have been involved for 5 years in an extensive breast cancer family collection and counseling which was at first dedicated to the positional cloning effort of the breast cancer susceptibility gene, *BRCA1* (12,13). *Since 7/1/94, under the direction of Dr. Sofia Merajver, the Breast Cancer Genetics Project has ascertained 114 new breast cancer families. Thirty of those families are in active collection, and 7 have been completely collected.* The principal sources of referrals are: the University of Michigan Breast Care Center (BCC) (450 new breast cancer patients a year), community surgeons, oncologists, and general practitioners; physicians at other research institutions. We have established a successful collaboration with researchers at Henry Ford Hospital (HFH) in Detroit, MI, where a large number (over 150/year) of African American and Hispanic breast cancer patients with a family history are diagnosed and treated. *The family collection at the University of Michigan has proven invaluable in the localization of BRCA1 and in the assessment of familial mutations. The collection provides a renewable source of RNA and*

DNA for functional studies after a tumor suppressor gene is cloned. The families ascertained through the research have the option of gaining knowledge of their risk if they so wish under approved protocols.

Linkage studies to 8p12-22 and other loci.

Fueled by the observation in several laboratories that fewer (10-20%) breast cancer families than previously anticipated (40-50%) are linked to *BRCA2*, other candidate loci such as 8p12-22 are being actively tested, where LOH has consistently been observed above background levels. Forty-seven percent of tumor samples have LOH here and at least one breast cancer family with a LOD (logarithm base 10 of the odds favoring linkage) score of 3.70 for markers in this locus has been described. The study of specific breast cancer families linked to the different loci will provide key information and materials for the understanding of these pathways. *The preliminary studies described here show that there is enough statistical evidence to pursue other tumor suppressor loci as putative familial cancer susceptibility genes on chromosomes 8p12-22 and 11p.*

Loss of heterozygosity (LOH)

Following Knudsen's "two-hit hypothesis" (19), loss of heterozygosity (LOH) is generally a marker of the presence of a tumor suppressor gene. S. Merajver has studied LOH in familial and sporadic breast and ovarian tumors for the last 4 years (4,12). *These experiments demonstrate that LOH at closely spaced, ordered markers on a tumor suppressor candidate region can define a minimum region of overlap and help localize the desired transcript. This experimental design can be extended to other tumor suppressor regions, such as 8p12-22.*

Mutation analyses of familial and sporadic specimens.

Advances in familial cancer syndromes are also relevant to sporadic carcinogenesis. For example, the PI and others have recently shown that *BRCA1* is implicated in sporadic carcinogenesis (4). Dr. Merajver's laboratory was the first to report 4 somatic mutations (12). The initial screen for mutations was performed by a modification of single-strand conformation polymorphism (SSCP) technique. *These experiments show that even for a fairly large gene such as BRCA1, thorough, semi-automated, batch-mode mutation analyses can be performed efficiently and rapidly with a combination of SSCP and direct sequencing of familial and sporadic tumors. Even in the complicated situation posed by BRCA1, these methods have proven effective; we believe that it is not overly optimistic to predict that they will serve us well for tumor suppressor genes on 8p12-22.*

SUMMARY OF PRELIMINARY STUDIES .

The PI has performed family collection studies (13), directs a high-risk breast cancer clinic where family members are counseled, has conducted detailed mapping studies of sporadic tumors by LOH (12), and has ascertained that the mutations of the first described familial breast cancer gene (*BRCA1*) are present in sporadic tumors (4). Research in all these areas has been published in the peer-reviewed literature. (4,12,13)

Body

The work performed in Dr. Merajver's laboratory under this grant is part of a multifaceted collaborative effort to understand the molecular genetics of familial and sporadic breast cancers. The laboratory efforts in this regard are now proceeding along 3 well-defined lines of investigation, as follows:

(1) Family linkage studies to 8p, *BRCA1*, and other genes.

The work on 8p involving families and tumors has progressed as follows, in accordance to the specific aims of the project.

We have proceeded with our studies of families with potential linkage to *BRCA3* putatively assigned to chromosomal region 8p12-22. In this project we have also ascertained 8 families in which affected individuals appear to share disease-associated 8p haplotypes. We are building a collaboration with investigators at Johns Hopkins

University Oncology Center in the search for breast cancer genes on 8p. We are planning on sending these investigators samples from these select families for further studies with unpublished markers in the region, and we will share with them the studies of mutations of any new genes identified. We have also ascertained 23 tumors with deletions at 8p of various sizes which we will share collaboratively with the Hopkins group.

We have expanded our family resources by continuing to build a cancer genetics network with several key institutions in the State. In particular, we have now joined forces and protocols with the Karmanos cancer Institute and Butterworth Hospital in Western Michigan. We continue to utilize the community resources we have gathered, and right now we have as many families as we can study (even with our collaborators) in the next year, approximately as planned in the SOW.

The collection of blood specimens has been undertaken in the manner in which we have proceeded so far, under an IRB-approved protocol. In brief, after signing informed consent, we draw 3 lavender-top tubes (5 cc each) for DNA and 2 green-top tubes (for lymphocyte immortalization). The DNA extraction and immortalization protocols are described below. Pre-paid mailing kits or travel to the family's domicile are used for remote specimens. This latter method is very cost-effective, allows for the establishment of close rapport with the family, and provides for an opportunity to answer questions regarding the research and breast cancer. The familiar specimen collection proceeded at an extremely fast pace, and, at present, except for striking families, we have more samples that we can realistically fully analyze in the next 8-12 months, so we are concentrating on the analyses primarily. We have extracted the DNA performed the LOH experiments on 8p. We are also poised to proceed in an expedient manner were the actual BRCA3 gene to be isolated by other labs in the near future. This portion of aim 1 is ahead of schedule as per the SOW.

(2) Linkage analyses.

Linkage analysis is performed using the method of LOD scores (14-16). Calculations are carried out with the programs MENDEL (15) and LINKAGE (16). All families will be screened for linkage to *BRCA1* with *D17S855* and *D17S1323*, two intragenic polymorphic markers, and *BRCA2*, the latter with *D13S221*, *D13S260*, *D13S267*, and *D13S263*. Following Kerangueven et al (2), we will use the following panel of markers on 8p12-22 (Table 1).

For each family not linked to either *BRCA1*, or *BRCA2*, or 8p12-22, rapid SSCP analyses of 2 affected individuals with age of onset of cancer under 50 were conducted on the *KAI1* gene on 11p11.2 (17). The primers for this gene were designed and synthesized, and tested on DNA from lymphocytes and archival materials. The results, however, were negative, and no alterations were found. For this reason, we modified our course and proceeded to actually isolate more genes involved in breast cancer progression and aggressive phenotypes, as summarized below. This entirely new area of investigation has proven extremely promising and successful, and was entirely spurred by this negative result..

TABLE 1. 8p markers to be used in this study ordered from centromere to telomere

Tumor LOH	Linkage studies
D8S137	D8S137
<i>NEFL</i>	<i>NEFL</i>
D8S259	
D8S133	D8S133
D8S258	
<i>LPL</i>	
D8S261	D8S261
D8S265	

The 8p markers have all been synthesized, tested on trial paraffin specimens (we are always extremely frugal with our valuable familial specimen resources), and optimized for amplification of paraffin-embedded material. The analyses of 50 familial and over 40 sporadic specimens along the 8p12-22 region will continue for the next 0.6-0.8 years, as per the SOW.

(3) Additional Projects. (Undertaken under this grant due to auspicious circumstances which modified and expanded the course of the research).

(3.1) BRCA2.

We ascertained 4 new BRCA2 families. We recognized 1 novel BRCA2 mutation on exon 11 which occurs in a breast/ovarian family. This is especially important in light of the phenotype-genotype correlation reported between exon 11 and the risk of ovarian cancer, as this mutation further reinforces that relationship.

(3.2) DIFFERENTIAL EXPRESSION OF GENES IN THE SUM149 CELL LINE WHICH MAY CONTRIBUTE TO THE PATHOGENESIS OF INFLAMMATORY BREAST CANCER.

Inflammatory breast cancer affects approximately 6% of all breast cancer patients in the United States. The disease is characterized by a dark red and swollen appearance of the skin overlying the breast which is caused by the infiltration and subsequent blockage of the lymph vessels by the carcinomatous emboli. Clinically, it is a rapidly growing tumor which is classified at diagnosis as a T4d (stage IIIb) carcinoma. Clinical evidence suggests that nearly all of women with inflammatory breast cancer have axillary nodal involvement at the time of diagnosis. Furthermore, it is estimated that at the time of diagnosis, 36% of women with inflammatory breast cancer have distant metastases; this number increases significantly within one year. Because of the prevalence of nodal and metastatic involvement, prognosis for long-term disease-free survival is guarded. At present, the genetic factors and pathways which underlie the pathogenesis of inflammatory breast cancer have yet to be elucidated.

To address this question, our laboratory has isolated and identified genes which are differentially expressed in normal versus inflammatory mammary tumor cells. Messenger RNA isolated from the SUM149 cell line, which was developed at the University of Michigan from an aggressive primary infiltrating ductal carcinoma, was compared with mRNA from the same patient's own lymphocytes and from two normal mammary epithelial cell lines. Comparison of the cDNAs from this system was accomplished using the differential display technique.

All differentially expressed messages were cloned and sequenced. Nine genes were shown to be expressed in the normal cells but not in the tumor cells. Of these genes, three out of nine are known genes; an olfactory receptor gene, *H-NUC* and *HMG-CoA reductase*. The protein products of the latter two genes have previously been implicated in breast cancer progression and the control of cell growth. H-NUC is a protein which is associated with the hypophosphorylated form of the tumor suppressor retinoblastoma protein. An increase in cell growth following loss of HMG-CoA reductase activity along with concurrent addition and stimulation of cells with growth promoters such as estrogen or epidermal growth factor has been previously demonstrated in some breast cancer cell lines. Additional breast tumor samples are being tested for mutations in these genes by SSCP analysis. The olfactory receptor genes are located on chromosome 17p13.1-17p13.3, an area which contains known tumor suppressor genes. No loss of heterozygosity was seen in the SUM149 cells at this or three other regions of chromosome 17, including *TP53* and *BRCA1*. The remaining six genes expressed exclusively by the normal mammary cells are novel and do not match any published sequence in the EST database. An additional group of four novel genes has been shown to be exclusively expressed in the tumor cells and match published sequences in the EST database.

(3.3) IDENTIFICATION OF GENES DIFFERENTIALLY METHYLATED IN INFLAMMATORY BREAST CANCER.

Inflammatory breast cancer affects only about 6% of breast cancer patients, but its metastatic potential and clinical manifestations contribute to its poor prognosis. To date, very few molecular mechanisms have been suggested which contribute to the progression of this disease. To identify one potential differential mechanism, we studied the methylation alterations of genes of the Sum 149 cell line (derived from a primary inflammatory breast cancer) as compared to normal human mammary epithelial cells, since altered gene methylations has been observed in cancers of many types. Fragments that showed differential methylation were cloned, sequenced, and used as probes in the Southern blot hybridization to confirm differential methylation. Ten of the thirteen candidate genes were found to be hypomethylated while the remaining three were hypermethylated in the tumor DNA. Three of the ten hypomethylated regions showed significant localization to chromosome 7. A hypomethylated gene encoding exon 2 of the human frataxin gene, which is known to be flanked by a cluster of CpG islands was also isolated. Mutations in this gene lead to Friedreich's ataxia an autosomal recessive neurodegenerative disorder. The remaining hypo and hypermethylated genes showed significant matches to a variety of sequences in the EST database. These results suggest that differential methylation of genes is a potentially important phenomenon in the pathogenesis of inflammatory breast cancer. Further investigations are underway to assess the functional significance of these changes.

List of Publications and Abstracts directly supported or partially supported by this grant (1996-1997).

PEER-REVIEWED PUBLICATIONS

1. Helvie MA, Joynt LK, Cody RL, Pierce LJ, Adler DD, Merajver SD: Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. *Radiology* 198:327-332, 1996.
2. Pierce L, Adler D, Helvie M, Lichter A, Merajver SD: The use of mammography in breast preservation in locally advanced breast cancer. *Int J Radiation Oncology Biol Phys* 34:571-577, 1996.
3. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ: Distinct regions of allelic loss on 13q in prostate cancer. *Cancer Research* 56:1142-1145, 1996.
4. Merajver SD and Petty EM: Risk assessment and presymptomatic molecular diagnosis in hereditary breast cancer. *Clinics in Laboratory Medicine* 16:139-167, 1996.
5. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver SD, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Goldgar DE, et al.: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. *Nat Genet* 12:333-337, 1996.
6. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidens D, Godwin AK, Daly M, Radford DM, Sedlacek S, Rommens J, Simard J, Garber J, Merajver SD, Weber BL: BRCA2 germline mutations in male breast cancer cases and breast cancer families. *Nat Genet* 13:123-125, 1996.

7. Simon JS, Deshmukh G, Couch FJ, Merajver SD, Weber BL, VanVooren P, Tissil F, Szpirer J, Szpirer C, Alper SL, Jacob HJ, Brossius FC, III: Chromosomal mapping of the rat *Slc4a* family of anion exchanger genes, *Ae1*, *Ae2* and *Ae3*: Mammal Genome 7:380-382, 1996.
8. Caduff RF, Johnston CM, Svoboda SM, Poy EL, Merajver SD, Frank TS: Clinical and pathologic significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 148 (5):1671-8, 1996.
9. Abel KJ, Brody LC, Valdes JM, Erdos MR, McKinley DR, Castilla LH, Merajver SD, Couch FJ, Friedman LS, Ostermeyer EA, Lynch ED, King MC, Welsh PL, Osborne-Lawrence S, Spillman M, Bowcock AM, Collins FS, Weber BL: Characterization of EZH1, a human homolog of *Drosophila Enhancer of zeste* near BRCA1. Genomics 37:161-171, 1996.
10. Helvie MA, Roubidoux MA, Weber BL, Merajver SD: Mammography of breast carcinoma in women who have the breast cancer gene BRCA1: initial experience. American Journal of Roentgenology 168:1599-1602, 1997.
11. Merajver SD, Weber BL, Cody R, Zhang D, Strawderman M, Calzone KA, LeClaire V, Levin A, Irani J, Helvie M, August D, Wicha M, Lichter A, Pierce LJ: Breast Conservation and Prolonged Chemotherapy for Locally Advanced Breast Cancer: The University of Michigan Experience. Journal of Clinical Oncology 15:2873-2881, 1997.

ABSTRACTS

12. Merajver SD, Pham TM, Ethier S: Characterization of BRCA1 transcription and expression in breast cancer cell lines. 1996 Keystone Symposium on Tumor Suppressor Genes, 1996.
13. van Golen KL, Hu H, Pham T, Sartor C, Ethier S, Merajver SD: EGF regulated BRCA1 expression in breast cancer cells by a MAP kinase pathway. 1997 Keystone Symposium on Genetics of Human Cancer: Pathogenesis and Diagnosis, January 1997.
14. Hu H, Pham T, Sartor C, Ethier S, van Golen KL, Merajver SD: EFG regulates BRCA1 expression in SUM102 breast cancer cells by a MAP kinase pathway. Poster Discussion Session, 1997 Annual Meeting of the American Association for Cancer Research.
15. van Golen KL, Davies S, Ethier SP, Merajver SD: Differential Expression of Genes in the SUM149 Cell Line Which May Contribute to the Pathogenesis of Inflammatory Breast Cancer. 1997 American Cancer Society's First Annual Schilling Research Conference, September 18-21, 1997.
16. LeClaire V, Taylor K, Merajver SD: A Mandate for the Future: The Multidisciplinary Cancer Risk Counseling Program. Michigan Nurse's Association Annual Conference, October 7, 1997.
17. LeClaire V, Taylor K, Merajver SD: A Cancer Genetics Education Program. Annual Great Lakes Cancer Nursing Conference, October 21-22, 1997.
18. Taylor KA, LeClaire V, Blumberg LR, Chen, P, Strecher V, Merajver SD: A Bilingual Educational Tool in Breast Cancer Genetics. 1997 National Society of Genetic Counselors 16th Annual Education Conference, 1997, October 26, 1997.

19. Taylor KA, LeClaire V, Simmermon, J. Merajver SD: Impact of Worry About Perceived Breast Cancer Risk Among Patients in a Breast and Ovarian Cancer Risk Evaluation Program. 1997 American Society of Human Genetics, October 31, 1997.
20. van Golen KL, Davies S, Ethier SP, Merajver SD: Differential Expression of Genes in the SUM149 Cell Line Which May Contribute to the Pathogenesis of Inflammatory Breast Cancer. 1997 U.S. Army Medical Research and Materiel Command Conference, October 31-November 4, 1997, Vol II, p 311.
21. Ethier SP, Merajver SD, Giordano T: Distribution of Human Breast Cancer Cells, Cell Lines and Tissues from the UM Breast Cancer Cell and Tissue Bank. 1997 U.S. Army Medical Research and Materiel Command Conference, October 31-November 4, 1997, Vol III, p 1053.

Conclusions

The work on 8p continues to prove encouraging that an important BRCA3-like gene is harbored by that chromosomal region. Our laboratory investigations of differentially expressed genes in aggressive breast cancers have led, in the last year, to striking progress. We are now poised to further study the newly isolated genes. We hope to devote the remainder of the grant period to this task, and to seek other sources of funding to continue this work in the near future.

References

1. Shattuck-Eidens D, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. *JAMA* 273:535-541 (1995).
2. Kerangueven F, et al. Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. *Oncogene* 10:1023-1026 (1995).
3. American Cancer Society: *Cancer Statistics*, CA 45:1-20 (1995).
4. Merajver SD, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. *Nature (Genetics)* 9:439-443 (1995).
5. Amos CI, Goldstein AM, Harris EL. Familiality of breast cancer and socioeconomic status in blacks. *Cancer Res.* 51:1793-7 (1991).
6. Schatzkin A, Palmer JR, Rosenberg L, Helmrich SP, Miller DR, Kaufman DW, Lesko SM, Shapiro S. Risk factors for breast cancer in black women. *J Natl Cancer Inst.* 78:213-7 (1987).
7. Bondy ML, Fueger JJ, Vogel VG, Spitz MR. Ethnic differences in familial breast cancer. *Proc Annu Meet Am Assoc Cancer Res.* 32:A1316 (1991).
8. Siraganian PA, Levine PH, Madigan P, Mulvihill JJ. Familial breast cancer in black Americans. *Cancer* 60:1657-60 (1991).
9. Weiss KM, et al. Familial aggregation of cancer in Laredo, Texas: a generally low-risk Mexican-American population. *Genet Epidemiol* 3:121-43 (1986).
10. Kato I, et al. A case-control study of breast cancer among Japanese women: with special reference to family history and reproductive and dietary factors. *Breast Cancer Res. Treat* 24:51-9 (1992).
11. Zidan J, Diab M, Robinson E. Familial breast cancer in Arabs. *Harefuah* 122:767-9, (1992).
12. Merajver SD, et al. Germline *BRCA1* mutations and loss of the wild-type allele in tumors from families with early-onset breast ovarian cancer. *Clin. Cancer Research* 1:539-544 (1995).

13. Hoskins KF, et al. Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. *JAMA* 273:577-585 (1995).
14. Morton NE. Sequential tests for the detection of linkage. *Am J Hum Genet* 7:277-318 (1955).
15. Lange K, Weeks D, Boehnke M. Programs for pedigree analysis: MENDEL, FISHER and dGENE. *Genet Epidemiol* 5:471-472 (1988).
16. Lathrop GM, Lalouel J-M. Efficient computations in multilocus linkage analysis. *Am J Hum Genet* 42:498-505 (1984).
17. Dong J-T, et al. *KAI1*, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. *Science* 268:884-886 (1995).
18. Castilla LH et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. *Nature (Genetics)* 8:387-91(1994).
19. Knudson AG. Antioncogenes and human cancer. *Proc Nat Acad Sci USA* 90:10914-10921(1993).